In the treatment of neovascular age-related macular degeneration (AMD), vascular endothelial growth factor (VEGF) has emerged as a key target of therapy. Currently, patients with neovascular AMD are treated with monthly intravitreal injections of anti-VEGF medications.
Introduction
In the USA, age-related macular degeneration (AMD) is the leading cause of vision loss in older patients. It is estimated that the prevalence of AMD is 6.5% among people aged 40 years and older [Klein et al. 2011] . AMD also remains a leading cause of vision loss among older adults in other Western countries. Most of this vision loss stems from advanced AMD. Advanced AMD can be classified into two major forms: the non-neovascular, atrophic (dry) form or the neovascular (wet) form. The majority of people with severe vision loss (20/200 or worse) from AMD have the neovascular form, which is estimated to occur in 10-20% of patients [Ferris et al. 1984] . Currently, there is no effective treatment for advanced, dry AMD [Meleth et al. 2011 ]. However, neovascular AMD has been successfully targeted by a number of treatment strategies.
Overview of current therapy
The hallmark of wet AMD is the formation of new, anomalous blood vessels that typically arise from the choroidal vasculature and can grow into the subretinal pigment epithelial or subretinal space. Rarely, this process may originate from the retina and extend posteriorly into the subretinal space, a form of neovascular AMD termed retinal angiomatous proliferation. These neovascular vessels commonly hemorrhage and leak and can compromise vision by distorting the retinal and subretinal architecture with fluid, blood, or fibrovascular tissue [Spilsbury et al. 2000 ]. Untreated, choroidal neovascularization (CNV) usually leads to permanents loss of central vision.
The pathogenesis of CNV is not completely understood. However, the overexpression of vascular endothelial grown factor (VEGF), a proangiogenic cytokine, has been shown to play a crucial role [Spilsbury et al. 2000 ]. Previous studies have demonstrated increased levels of VEGF in the presence of inflammatory cytokines, suggesting that inflammation is a key component of AMD [Nagineni et al. 2012] . Others have suggested that ischemia, also associated with increased VEGF [Witmer et al. 2003 ], may play a role in AMD [Feigl, 2009] . All of these reports clearly indicate that VEGF is vital to the pathogenesis of CNV in AMD.
Early treatment strategies focused on destruction of choroidal neovascular membranes using laser photocoagulation. The Macular Photocoagulation Study (MPS) established guidelines for treatment of these lesions [Macular Photocoagulation Study Group, 1982 , 1986 , 1991 . Although this treatment reduced the likelihood of severe vision loss compared with the natural course of the disease, there were many limitations, especially when treating lesions in the fovea. The primary downsides were related to the fact that the laser induced a permanent scotoma, and recurrence of the CNV occurred in over 50% of treated eyes [Macular Photocoagulation Study Group, 1991] .
Until 1999, laser photocoagulation was the only treatment for neovascular AMD that had been shown to reduce the risk of vision loss. At that time, the Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study reported that photodynamic therapy (PDT) with verteporfin (Visudyne; Novartis Pharma AG, Basel, Switzerland) reduced the risk of moderate to severe vision loss for at least 5 years in patients who presented with subfoveal lesions classified as predominantly classic [TAP Study Group, 1999; Azab et al. 2004; Blumenkranz et al. 2002; Bressler and TAP Study Group, 2001; Bressler et al. 2002; ]. PDT is a two-step process that involves the intravenous injection of verteporfin, a photosensitizing molecule, which is taken up by dividing cells within CNV. The drug is activated by local application of energy from a diode laser source at a wavelength that corresponds to an absorption peak of the molecule. A photochemical reaction occurs and activated free radicals are generated that can lead to capillary endothelial cell damage and vessel thrombosis. At 2 years, 59% of verteporfin treated eyes versus 31% of placebo eyes avoided at least moderate vision loss [Bressler and TAP Study Group, 2001] . While PDT improved the results seen with laser photocoagulation, there remained a pressing need for better treatment modalities.
The first VEGF inhibitor to obtain US Federal Drug Administration (FDA) approval for CNV in AMD was pegaptanib (Macugen; OSI/ Eyetech Pharmaceuticals, New York, NY, USA) in 2004. Pegaptanib is an RNA aptamer that binds human VEGF 165 with high affinity and specificity [Gragoudas et al. 2004 ]. The drug, however, did not bind other active VEGF isoforms such as VEGF 121 . Pegaptanib is administered as an intravitreal injection every 6 weeks. The VEGF Inhibition Study in Ocular Neovascularization (VISION) trial was a prospective, randomized, double-masked, controlled, dose-ranging phase III clinical trial in which 1186 patients with AMD and subfoveal CNV received one of three doses of pegaptanib or sham injections every 6 weeks for 48 weeks [Gragoudas et al. 2004] . The results of this study were promising, with 70% of patients losing less than three lines of vision compared with 55% of controls (p < 0.001). Unfortunately, similar to the results with PDT, a minority of patients gained vision with this therapy.
One of the most exciting advances in the treatment of CNV in AMD came with the introduction of ranibizumab (Lucentis; Genentech, South San Francisco, CA, USA) in 2006. Ranibizumab is a recombinantly produced, humanized, antibody (Fab) fragment that binds VEGF [Rosenfeld et al. 2006 ]. Unlike pegaptanib, ranibizumab binds to and inhibits the biological activity of all active forms of VEGF-A. The Minimally Classic/Occult Trial of the Anti-VEGF Antibody Ranibizumab in the Treatment of Neovascular AMD (MARINA) study was a randomized, double-masked, sham-controlled clinical trial of 716 patients with minimally classic or occult CNV secondary to AMD treated with one of two different doses of intravitreal ranibizumab or sham injections given every 4 weeks for 2 years [Rosenfeld et al. 2006 ]. The results of this study were revolutionary with 94.5% of patients treated with ranibizumab 0.3 mg and 94.6% of patients treated with ranibizumab 0.5 mg experiencing vision stabilization or improvement compared with 62.2% of patients receiving sham injections (p < 0.001). In fact, visual acuity improved by 15 letters or more in 24.8% of patients receiving 0.3 mg and 33.8% of patients receiving 0.5 mg ranibizumab compared with 5.0% of the sham injection group (p < 0.001). These results were further supported by the Anti-VEGF Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization in AMD (ANCHOR) study, which was a randomized, controlled, double-masked phase III clinical trial of 423 patients that compared patients treated with ranibizumab with patients treated with PDT with verteporfin treatment [Brown et al. , 2009 . These results showed that 94.3% of patients treated with 0.3 mg ranibizumab and 96.4% of patients treated with 0.5 mg ranibizumab lost less than 15 letters of vision compared with 64.3% of patients treated with PDT at 1 year (p < 0.001). Patients receiving ranibizumab again showed increased vision in 35.7% of patients treated with 0.3 mg ranibizumab and 40.3% of patients treated with 0.5 mg ranibizumab compared with only 5.6% of patients treated with PDT (p < 0.001). The results of these trials resulted in anti-VEGF therapies largely replacing previous treatment modalities.
Bevacizumab (Avastin; Genentech) is a fulllength monoclonal antibody that binds all isoforms of VEGF-A. The FDA originally approved it in February 2004 for the treatment of metastatic colorectal cancer. Soon thereafter, physicians started to use it off label as an intravenous or intravitreal treatment for neovascular AMD. Despite the lack of clinical research to support its safety or efficacy, anecdotal evidence led to its widespread popularity prior to the approval of ranibizumab in 2006. To deliver an intravitreal injection, a physician or pharmacy takes a vial of bevacizumab and makes numerous unit doses. This dramatically lowers the cost of the drug. The approximate cost differential between ranibizumab (US$2000) and bevacizumab (US$S50) was prohibitive for some patients, and bevacizumab continued to be utilized, despite not being FDA approved for intravitreal use. In fact, in a review of Medicare claims for neovascular AMD in 2008, it was noted that 58% of all intravitreal injections given were bevacizumab and 41% were ranibizumab [Brechner et al. 2011 ].
To address the safety and therapeutic concerns of the widespread, off-label use of bevacizumab in the treatment of wet AMD, the National Eye Institute commissioned the Comparison of Age-Related Macular Degeneration Treatment Trial (CATT) [CATT Research Group et al. 2011] . In this multicenter, single-blind, noninferiority trial, 1208 patients with neovascular AMD were randomized into four groups. After the first mandatory intravitreal injection, patients received ranibizumab every 28 days (ranibizumab monthly), bevacizumab every 28 days (bevacizumab monthly), ranibizumab only when signs of active neovascularization were present (ranibizumab as needed), and bevacizumab only when signs of active neovascularization were present (bevacizumab as needed). The 1-year results of this study demonstrated that monthly bevacizumab was equivalent to monthly ranibizumab with 8.0 and 8.5 letters gained, respectively. Bevacizumab as needed was found to be equivalent to ranibizumab as needed with 5.9 and 6.8 letters gained, respectively. While ranibizumab as needed was found to be equivalent to ranibizumab monthly, the equivalence of bevacizumab as needed compared with bevacizumab monthly was found to be inconclusive.
Aflibercept
Aflibercept (Eylea; Regeneron, Tarrytown, NY, USA and Bayer, Basel, Switzerland) is a fully human, recombinant fusion protein composed of the second immunoglobulin (Ig) binding domain of VEGF receptor 1 and the third Ig binding domain of VEGF receptor 2, fused to the Fc region of human IgG1. It binds to all VEGF-A isoforms, VEGF-B, and placental growth factor (PlGF) [Papadopoulos et al. 2012] . Aflibercept is a member of Regeneron's proprietary family of 'Trap' products that catch, hold, and block (i.e. trap) certain cytokines [Adis R&D Profile, 2008] . Aflibercept is being developed for the treatment of cancer (Zaltrap; Regeneron and Sanofi, Bridgewater, NJ, USA) and eye disorders. The eye formulation, also referred to in the literature as VEGF Trap-Eye, is identical in structure to the intravenous cancer treatment, with further purification steps and buffer modification to allow for comfortable, nonirritating intravitreal injection [Dixon et al. 2009 ].
Unlike currently available anti-VEGF therapies, aflibercept binds PlGF in addition to all isoforms of VEGF-A and VEGF-B. Like VEGF, PlGF is present in human CNV membranes, and animal studies have shown that PlGF contributes to the development of experimental CNV [Rakic et al. 2003 ]. Another differentiating feature of aflibercept is that the binding affinity for VEGF is 0.5 pM Kd, which is considerably stronger than ranibizumab, bevacizumab, or native VEGF receptors. This allows for effective blocking of VEGF, even at low concentrations, which may translate into a longer duration of action and extended dosing intervals [Stewart and Rosenfeld, 2008] .
The results of preclinical studies were promising. In Matrigel-induced models of CNV in rats, aflibercept was shown to arrest the growth of CNV and led to the regression of recently established lesions [Cao et al. 2010] . Primate studies of laserinduced CNV also showed promise for the drug. When aflibercept was given prior to and following attempted laser induction of CNV, minimal neovascularization was noted compared with placebo. In drug-naïve eyes with previously established CNV, aflibercept was successful in causing regression of the CNV and resolving vascular leakage [Nork et al. 2011 ]. These encouraging results coupled with the apparent safety of the drug, fueled the demand for human clinical trials.
Phase I
A phase I, randomized, multicenter, masked, placebo-controlled clinical trial of intravenous aflibercept in patients with subfoveal CNV from AMD showed a dose-dependent decrease in retinal thickness [Nguyen et al. 2006 ]. However, at systemic doses of 3 mg/kg, hypertension and proteinuria were observed, and the study was halted for safety concerns. This led to investigation of alternative delivery methods.
The safety, tolerability, maximum tolerated dose, and bioactivity of intravitreal injection of aflibercept were evaluated in a phase I, multicenter, dose-escalation study [Nguyen et al. 2009 ]. In the study, 21 patients received a single dose of aflibercept. Patients were monitored for 12 weeks after injection. There were no serious ocular or systemic events noted. With any dose of aflibercept, stable or improved vision was seen in 95% of patients at 6 weeks. The mean decrease in foveal thickness was −105.5 µm, and the mean increase in visual acuity was +4.43 letters. Half of the patients receiving 2 or 4 mg doses showed no retinal leakage and maintained vision gains at 12 weeks after a single injection. These positive results paved the way for further development of an intravitreal formulation of aflibercept.
Phase II
The clinical evaluation of anti-angiogenesis in the retina study (CLEAR-IT) 2 trial was a phase II multicenter, prospective, randomized, doublemasked clinical trial designed to study the effect of intravitreal aflibercept in patients with neovascular AMD [Brown et al. 2011; Heier et al. 2011 ]. This trial was divided into two parts. In the first part, patients were treated with a fixed dosing interval up to 12 weeks. The second part of the study was designed to be as needed (PRN) dosing and took place from week 16 to 52. The primary endpoint of the study was the change in central retinal thickness. The mean change in best corrected visual acuity (BCVA) was evaluated as a secondary outcome. The study included 159 patients who were randomized into five treatment groups. The first two groups received treatment every 4 weeks and were dosed at 0.5 mg (group 1) or 2 mg (group 2). The last three groups were treated every 12 weeks and were dosed at 0.5 mg (group 3), 2 mg (group 4), or 4 mg (group 5). The primary outcome was at 12 weeks, following the fixed dosing period. The mean decrease in central retinal thickness from baseline to 12 weeks in all groups was −119 µm. Monthly dosing with either 0.5 or 2 mg (groups 1 and 2) provided a more profound and consistent effect than any of the groups treated every 12 weeks. Overall, there was a mean increase in BCVA of +5.7 Early Treatment Diabetic Retinopathy Study (ETDRS) letters in all groups. The greatest mean increase in BCVA, more than +8 letters, was seen in the monthly dosing groups compared with the patients receiving only one injection [Brown et al. 2011 ].
For the PRN dosing arm of the study, patients were evaluated every 4 weeks to determine the need for continued treatment. Patients received an injection of the baseline dose at week 12. At week 16 and thereafter, eyes were reinjected with aflibercept if any of the following conditions were noted: increase in central retinal thickness of at least 100 µm by optical coherence tomography (OCT); loss of at least 5 ETDRS letters with recurrent fluid on OCT; persistent fluid on OCT; new-onset of classic CNV; new or persistent leak on fluorescein angiography; or new macular hemorrhage on clinical examination. Using these criteria, the mean decrease in central retinal thickness in all groups from baseline to 52 weeks was −130 µm. The mean increase in BCVA was +5.3 ETDRS letters in all groups. The greatest increase in BCVA occurred in the group initially treated with 2 mg every 4 weeks for 12 weeks before PRN dosing with a mean increase of +9.0 letters at 1 year. To achieve these excellent visual gains, an average of two additional injections was administered after the 12-week fixed-dosing phase across all groups. The mean time to the first reinjection was 129 days, with 19% of patients receiving no injections and 45% receiving one or two additional injections .
Phase III Two parallel, phase III, double-masked, randomized studies were initiated in August 2007. The VEGF Trap-Eye: Investigation of Efficacy and Safety in wet Age-Related Macular Degeneration (VIEW 1) study was performed in North America. The VIEW 2 study was an international study including Europe, Asia Pacific, Japan, and Latin America. The studies were designed as noninferiority studies comparing intravitreal aflibercept with ranibizumab. Patients with subfoveal CNV due to AMD were randomized into four groups. The first two groups received intravitreal injections of aflibercept at doses of 0.5 and 2 mg administered at 4-week intervals. The third group received 2 mg of aflibercept at 8-week intervals following three loading doses given every 4 weeks. These were compared with the fourth group, the control, receiving 0.5 mg of ranibizumab administered every 4 weeks. The primary endpoint was statistical noninferiority in the proportion of patients who maintained or improved vision over 52 weeks compared with ranibizumab.
The 1-year results of the VIEW 1 study showed that vision was maintained, defined as losing fewer than 15 ETDRS letters, in 96% of patients receiving aflibercept 0.5 mg monthly, 95% of patients receiving 2 mg monthly, and 95% of patients receiving 2 mg every 2 months. These results compared favorably with the 94% of patients maintaining vision in the group receiving ranibizumab 0.5 mg monthly [Regeneron, 2010; Heier, 2011] . The patients receiving aflibercept 2 mg monthly on average gained 10.9 letters compared with a mean 8.1 letter gain with ranibizumab 0.5 mg dosed every month (p < 0.01). The VIEW 2 study showed similar results, with maintenance of vision in 96% of patients receiving 0.5 mg monthly, 96% of patients receiving 2 mg monthly, and 96% of patients receiving 2 mg every 2 months. These results also compared favorably with the 94% of patients maintaining vision in the group treated with ranibizumab 0.5 mg monthly [Schmidt-Erfurth, 2011] . They are similar to results found in the MARINA and CATT trial (Table 1 ). The safety of both VIEW 1 and VIEW 2 studies was excellent with no difference seen between any aflibercept group and the ranibizumab group. The fact that 2 mg aflibercept dosed every 8 weeks after three loading doses was noninferior to ranibizumab dosed every 4 weeks in terms of safety and efficacy is exciting, as it offers the hope of similar visual gains with less treatment burden.
The 2-year results of the VIEW 1 and VIEW 2 studies were recently released [Regeneron, 2011] . The integrated analysis of these two studies (Table 2) shows that patients receiving aflibercept 2 mg every 8 weeks gained +7.6 letters from baseline at week 96 compared with +8.4 letters at week 52. The visual acuity gain in from baseline in patients receiving monthly ranibizumab was +7.9 letters at week 96 compared with +8.7 letters at week 52. Patients receiving aflibercept 2 mg every 8 weeks received an average of 11.2 injections over 2 years while patients treated with ranibizumab had an average of 16.5 injections over 2 years. Aflibercept (Eylea) was approved by the FDA for the treatment of wet AMD on 18 November 2011.
Conclusions
The evolution of treatment strategies for neovascular AMD has resulted in a paradigm shift in terms of expectations among patients and physicians. Prior to these recent advances, patients who developed neovascular changes could anticipate a progressive and permanent decrease in vision. While destruction of the CNV lesion with laser photocoagulation was possible, in particular when the lesion was located outside of the visual axis, it offered only modest hope of maintaining vision compared with the natural history of the disease, and results were less than satisfactory. The introduction of PDT with verteporfin offered some improvement, especially to patients with subfoveal disease. However, many patients continued to lose vision, and only minimal visual gains were achieved.
The advent of anti-VEGF therapy marked a turning point in the treatment of neovascular AMD. The first FDA-approved anti-VEGF therapy for neovascular AMD was pegaptanib. Unfortunately, the specific targeting of VEGF 165 seemed to limit its effectiveness, and as with PDT, patients generally continued to slowly lose vision. It was the phase III results of ranibizumab and the off-label intravitreal use of the cancer drug, bevacizumab, that began to change expectations. Anecdotal evidence of improvements in vision and retinal thickness after a single treatment were reported in patients whose condition had failed to respond to pegaptanib therapy [Rosenfeld et al. 2005] . With the publication of the ANCHOR and MARINA trials, and the subsequent FDA approval of ranibizumab, vision could be expected to stabilize in close to 95% of cases, with improvement of BCVA by three or more lines in approximately 40% of patients.
While anti-VEGF therapy has changed the efficacy of treatment, it is not without drawbacks. Patients are subjected to intravitreal injections as often as every 4 weeks to maintain vision. Frequent office visits, testing, and medication costs represent a burden to patients, physicians, and society. Although there have been no proven, adverse systemic effects from intravitreal injections, every injection puts patients at risk for endophthalmitis, intraocular inflammation, vitreous hemorrhage, retinal tear, retinal detachment, and iatrogenic cataract. Recent studies have also suggested a sustained rise in intraocular pressure may occur with serial injections of anti-VEGF agents [Tseng et al. 2011] . Aside from serious complications, patients are commonly subject to anxiety, discomfort, and the undesirable aesthetics of conjunctival hyperemia or hemorrhage.
Current efforts have focused on extending the benefits of anti-VEGF treatment with less frequent dosing. In the phase IIIb, multi-center, randomized, double-masked, sham injectioncontrolled study of efficacy and safety of ranibizumab in subjects with subfoveal CNV with or without Classic CNV secondary to AMD (PIER) study, patients received monthly injections of ranibizumab for 3 months followed by quarterly dosing. Gains in visual acuity were noted at 3 months, only to be lost during the quarterly dosing phase of the trial [Regillo et al. 2008 ]. In the prospective optical coherence tomography OCT imaging of patients with neovascular age-related macular degeneration treated with intra-ocular lucentis (PrONTO) study patients also received monthly injections of ranibizumab for 3 months. Following the initial dosing, additional treatments were given on a PRN basis. After 2 years, 78% of patients maintained vision and 43% of patients showed improvement in more than three lines of vision. An average of 9.9 injections was given over the 2-year period [Lalwani et al. 2009 ].
One of the criticisms of PRN dosing is the fact that monthly visits are still required. One approach to treatment that aims to reduce the number of injections and visits is the 'inject and extend' method [Spaide, 2007] . This strategy involves treatment with 3-monthly injections followed by a follow up appointment extended to 6 weeks. At the follow-up visit OCT and biomicroscopy are performed. If edema or any other sign of exudation is present, the patient is given an injection and told to follow up in 4 weeks. Patients without any evidence of exudation are injected and have their follow-up visit extended to 8 weeks. The same evaluation occurs at the 8-week visit. However, patients with signs of exudation are injected and scheduled to follow up at 6 weeks. Patients without evidence of exudation are further extended to follow up at 10 weeks. In this way, an optimal, individualized treatment strategy can be obtained. While a few small studies have reported positive results with this method, there have been no large, prospective studies to support its effectiveness [Engelbert et al. 2009; Oubraham et al. 2011 ].
Twelve-month results from the VIEW 1 and VIEW 2 studies appear promising for aflibercept. Although the data will have to be analyzed further, the apparent noninferiority of the various aflibercept dosing regimens compared with ranibizumab represents a new milestone in the treatment of CNV due to AMD. Of particular interest is the 2 mg every 8 weeks dosing interval studied in the trials. The recent results of the 2-year data for the VIEW 1 and VIEW 2 studies have further demonstrated the ability of aflibercept to maintain the visual gains attained in the first year of the study with a significantly smaller number of injections compared with ranibizumab. Aflibercept was recently approved by the FDA for the treatment of CNV in AMD. The wholesale price of aflibercept (US$1850) is slightly below that of ranibizumab. However, the reduced treatment requirements of every 8-week dosing versus monthly dosing of ranibizumab may represent a substantial savings in cost and treatment burden to patients.
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